Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Izumi Ohno's publication output changed over time?
ScholarIQpublication output · 1985–2024
Output grew0% over the shown period — from 1 works in 1985 to 1 in 2024.
1
1
1
1
1
1
1
3
1
198519912007200820132015201820192024
What are the most-cited papers on Izumi Ohno?
ScholarIQmost cited works
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu, Yoon‐Koo Kang, Chia‐Jui Yen, Richard S. Finn, Peter R. Galle, Josep M. Llovet, Eric Assénat, Giovanni Brandi, Marc Pracht, Ho Yeong Lim, Kun‐Ming Rau, Kenta Motomura, Izumi Ohno, Philippe Merle, Bruno Daniele, Dong Bok Shin, Guido Gerken, Christophe Borg, Jean‐Baptiste Hiriart, Takuji Okusaka, Manabu Morimoto, Yanzhi Hsu, Paolo Abada, Masatoshi Kudo
The Lancet Oncology. 20191,664 Citations
Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study
Makoto Ueno, Masafumi Ikeda, Chigusa Morizane, Satoshi Kobayashi, Izumi Ohno, Shunsuke Kondo, Naohiro Okano, Keisuke Kimura, Suguru Asada, Yoshinobu Namba, Takuji Okusaka, Junji Furuse
The Lancet. Gastroenterology & hepatology. 2019334 Citations
Anodic Oxidation of Reductants in Electroless Plating
Izumi Ohno, Osamu Wakabayashi, Shirō Haruyama
S138759888. 1985260 CitationsOPEN ACCESS
Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer
Shuichi Mitsunaga, Masafumi Ikeda, Satoshi Shimizu, Izumi Ohno, J. Furuse, Masatoshi Inagaki, Sayumi Higashi, Hiroyuki Kato, Keiji Terao, Atsushi Ochiai
British Journal of Cancer. 2013154 CitationsOPEN ACCESS
Related on ScholarIQ
Chiba University
Institution
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Paper
Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study
Paper
Anodic Oxidation of Reductants in Electroless Plating
Paper
Electrochemistry of electroless plating
Paper
Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer
Paper